Nodar Sulashvili

Prof. Dr. Nodar Sulashvili

Medicine and Pharmacology, Georgian National University SEU, Tbilisi, Georgia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2025 in GEORGIAN SCIENTISTS
Verified
Journal Article
Open access
PDF file
DADavid Aphkhazava
David Aphkhazava
Nodar SulashviliNodar Sulashvili
Nodar Sulashvili
Jaba TqemaladzeJaba Tqemaladze
Jaba Tqemaladze
Stem cell systems are pivotal in biological development, tissue maintenance, and regenerative medicine due to their dual capacity for self-renewal and differentiation. This review explores the heterogeneity and regulatory mechanisms governing stem cells across potency states—pluripotent, multipotent, and unipotent—emphasizing dynamic transcriptional circuits involving core factors (OCT4, SOX2, NANOG) and signaling pathways (Wnt/β-catenin, Notch, Hedgehog). Stem cell homeostasis, critical for tissue integrity, is maintained through intrinsic (epigenetic, metabolic) and extrinsic (niche-derived) cues, with disruptions linked to aging, degenerative diseases, and cancer. Advances in induced pluripotent stem cells (iPSCs) and genome editing (CRISPR-Cas9) offer transformative potential for personalized therapies, yet challenges such as tumorigenicity, immune rejection, and ethical concerns persist. The role of stem cell niches in modulating quiescence, proliferation, and differentiation is highlighted, alongside applications in tissue engineering, organoid development, and disease modeling. Aging-associated decline in stem cell function, driven by oxidative stress, DNA damage, and epigenetic alterations, underscores the need for rejuvenation strategies. Furthermore, dysregulated transcriptional networks in cancer stem cells (CSCs) present therapeutic targets for precision oncology. Future directions emphasize single-cell multiomics, synthetic biology, and bioengineered niches to refine differentiation protocols and enhance clinical translation. By integrating molecular insights with technological innovations, stem cell research promises to bridge gaps in regenerative medicine, offering novel solutions for degenerative disorders, injury repair, and personalized healthcare.

3 August 2025 in GEORGIAN SCIENTISTS
Verified
Journal Article
Open access
PDF file
DADavid Aphkhazava
David Aphkhazava
Nodar SulashviliNodar Sulashvili
Nodar Sulashvili
GMGeorge Maglakelidze
George Maglakelidze
Jaba TqemaladzeJaba Tqemaladze
Jaba Tqemaladze
While aging is a nearly universal biological process, certain species exhibit negligible senescence, maintaining reproductive capacity and physiological function over extended lifespans. Notable examples include the Greenland shark (exceeding 400 years), naked mole-rat (over 30 years), ocean quahog (507 years), and Hydra (theoretically immortal). These organisms defy typical aging patterns through enhanced DNA repair, oxidative stress resistance, robust stem cell maintenance, and unique proteostasis and epigenetic regulation. Comparative analysis reveals common adaptations such as: 1) late age of sexual maturation; 2) long-term maintenance of sexual activity; 3) reduced metabolic rate; 4) tolerance to hypoxia; 5) neoplastic suppression. The molecular mechanisms underlying their longevity—including high-molecular-weight hyaluronan in naked mole-rats and specialized lipid membranes in sharks—offer transformative insights for anti-aging interventions. Understanding these strategies could pave the way for novel therapies targeting age-related diseases, potentially redefining human healthspan. This review synthesizes current knowledge on negligibly senescent species, highlighting their evolutionary, physiological, and biomedical significance.

7 February 2025 in JUNIOR RESEARCHERS
Verified
Journal Article
Open access
PDF file
Nodar SulashviliNodar Sulashvili
Nodar Sulashvili
RNRishikesh Ranjit Nimangre
Rishikesh Ranjit Nimangre
Cardiovascular diseases (CVDs) represent a leading cause of morbidity and mortality worldwide, with a complex interplay of risk factors contributing to their prevalence. The manifestation of these diseases involves a range of pathophysiological processes, including but not limited to atherosclerosis, hypertension, and heart failure. This abstract aims to explore key aspects of cardiovascular diseases, focusing on their implications, pharmacotherapeutic strategies, effects, impacts, and potential hazards. The implications of cardiovascular diseases extend beyond individual health, influencing healthcare systems, economies, and societies at large. Early detection and management are critical for mitigating the disease burden. Pharmacotherapeutic interventions, such as antihypertensive agents, statins, and antiplatelet therapies, have proven effective in managing risk factors and improving patient outcomes. However, these treatments are not without challenges, as they often require individualized approaches to address the diverse genetic, environmental, and lifestyle factors that influence the progression of cardiovascular conditions. The effects of cardiovascular diseases are multifaceted, ranging from acute events, such as myocardial infarctions and strokes, to chronic conditions like heart failure. These diseases significantly impair the quality of life, necessitating long-term medical care and lifestyle modifications. The impacts of CVDs also extend to economic strain, particularly due to the costs associated with hospitalizations, medications, and rehabilitation. Potential hazards of pharmacological treatments, while necessary, must be carefully weighed against their benefits. Side effects, drug interactions, and long-term consequences are important considerations for clinicians in prescribing the most appropriate therapies for individual patients. Advances in precision medicine and personalized care offer promise for minimizing risks and optimizing treatment outcomes in cardiovascular care. The multifactorial nature of cardiovascular diseases requires an integrated approach to management, incorporating both preventive measures and effective therapeutic strategies. Ongoing research and innovation in pharmacology, as well as a deeper understanding of disease mechanisms, are essential for reducing the burden of cardiovascular diseases and enhancing patient quality of life. Cardiovascular diseases (CVDs) are among the leading causes of death and disability worldwide, affecting millions of individuals across various age groups and demographics. The manifestation of these disorders involves a wide spectrum of pathophysiological mechanisms, including atherosclerosis, arrhythmias, myocardial infarction, heart failure, and stroke. These diseases are influenced by both modifiable and non-modifiable risk factors, such as hypertension, diabetes, smoking, and genetic predisposition. This abstract examines the critical aspects of cardiovascular diseases, emphasizing their implications, pharmacotherapeutic strategies, effects, impacts, and potential hazards. კარდიოვასკულური დაავადებები (კდ) წარმოადგენს ჯანმრთელობის გაუარესების და სიკვდილის ერთ-ერთ მთავარ მიზეზს მსოფლიოში, რაც მოიცავს რისკ ფაქტორების რთულ ურთიერთობას, რომლებიც გავლენას ახდენენ მათ გავრცელებაზე. ამ დაავადებების გამოვლენა მოიცავს სხვადასხვა პათოფიზიოლოგიურ პროცესებს, მათ შორის, მაგრამ არა მხოლოდ, ათეროსკლეროზი, ჰიპერტენზია და გულის უკმარისობა. ეს რეზიუმე მიზნად ისახავს კარდიოვასკულური დაავადებების უმნიშვნელოვანეს ასპექტებზე განხილვას, მათ შორის...

26 November 2024 in GEORGIAN SCIENTISTS
Verified
Journal Article
Open access
PDF file
Nodar SulashviliNodar Sulashvili
Nodar Sulashvili
MDMagda Davitashvili
Magda Davitashvili
NGNana Gorgaslidze
Nana Gorgaslidze
LGLuiza Gabunia
Luiza Gabunia
MBMargarita Beglaryan
Margarita Beglaryan
MSMarika Sulashvili
Marika Sulashvili
Aim of the research was to study and analyze some issues of features of using of car-t cells in immunotherapy. The characterization of CAR-T cell products involves evaluating their phenotype, genotype, and functional attributes using techniques such as flow cytometry, PCR-based assays, and cytotoxicity assays. Long-term stability studies assess product viability, potency, and cytokine secretion profiles across different storage conditions to determine shelf-life and facilitate product logistics. Biomarkers serve as crucial tools in the field of cancer immunotherapy, aiding in patient selection and treatment optimization. In the context of chimeric antigen receptor (CAR) T cell therapy, biomarkers play a significant role in predicting treatment response, identifying potential toxicities, and guiding personalized treatment approaches. Predictive biomarkers in CAR-T cell therapy commonly center on the profiles of tumor antigen expression. The selection of target antigens plays a crucial role in treatment outcomes, with higher and more consistent expression levels correlating with better response rates. The tumor microenvironment (TME) significantly influences CAR-T cell activity. Biomarkers reflecting TME features, such as immune cell infiltration, cytokine profiles, and expression of inhibitory molecules, offer insights into the immunosuppressive nature of the TME and its effects on CAR-T cell effectiveness. Patients with an inflamed TME, marked by abundant effector T cells and low expression of inhibitory molecules like PD-L1, tend to respond better to CAR-T cell therapy. CAR-T cells demonstrate bystander killing effects, where nearby tumor cells without the target antigen are eradicated via a phenomenon called antigen spreading. This process is triggered by the release of cytokines and the presentation of tumor antigens by antigen-presenting cells (APCs), resulting in the activation of the body's own immune effector cells against the tumor cells. CAR-T cells exhibit strong antitumor capabilities, they can face resistance mechanisms within the tumor microenvironment. The immunosuppressive cell populations like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), as well as inhibitory cytokines such as transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10). The resistance mechanisms, strategies involve employing combination therapies with immune checkpoint inhibitors, cytokine modulators, and targeted therapies aimed at disrupting immunosuppressive pathways. CAR-T cell therapy has revolutionized cancer treatment by harnessing the power of the immune system to target and eliminate tumor cells. კვლევის მიზანი იყო იმუნოთერაპიაში CAR-T უჯრედების გამოყენების თავისებურებების ზოგიერთი საკითხის შესწავლა და ანალიზი. CAR-T უჯრედების პროდუქტების დახასიათება მოიცავს მათი ფენოტიპის, გენოტიპის და ფუნქციური ატრიბუტების შეფასებას ისეთი ტექნიკის გამოყენებით, როგორიცაა ნაკადის ციტომეტრია, PCR-ზე დაფუძნებული ანალიზი და ციტოტოქსიკურობის ანალიზი. გრძელვადიანი სტაბილურობის კვლევები აფასებს CAR-T უჯრედების სიცოცხლისუნარიანობას, პოტენციალს და ციტოკინის სეკრეციის პროფილებს შენახვის სხვადასხვა პირობებში შენახვის ვადის დასადგენად და პროდუქტის ლოგისტიკის...

22 February 2025 in JUNIOR RESEARCHERS
Verified
Journal Article
Open access
PDF file
Nodar SulashviliNodar Sulashvili
Nodar Sulashvili
UYUdgam Yaduvanshi
Udgam Yaduvanshi
MYMohini Yadav
Mohini Yadav
LGLuiza Gabunia
Luiza Gabunia
KGKetevan Ghambashidze
Ketevan Ghambashidze
ELEkaterine Lomia
Ekaterine Lomia
Vasoconstrictors are widely used in medical and dental practice, particularly in local anesthetics, to prolong drug efficacy and minimize systemic absorption. While these agents are generally considered safe, concerns have been raised regarding their effects on the cardiovascular system, particularly in patients with pre-existing heart conditions. The study examines the role of vasoconstrictors, their pharmacological mechanisms, and their potential risks and benefits in clinical settings. By analyzing modern literature and clinical guidelines, were provided conclusions and recommendations for the safe use of vasoconstrictors in patients with cardiovascular risks. The study of vasoconstrictors and their impact on cardiac function is a crucial area of cardiovascular research are very challenging in medicine. Vasoconstrictors are substances that cause the narrowing of blood vessels, leading to increased vascular resistance and blood pressure. The paper explores the scientific discourse surrounding the physiological mechanisms through which vasoconstrictors exert their effects on the cardiovascular system, focusing on their role in modulating cardiac output, myocardial oxygen demand, and overall cardiac function. The article delves into the molecular pathways involved, such as the activation of adrenergic receptors, the renin-angiotensin-aldosterone system, and endothelin, as well as their potential therapeutic implications and risks. The review discusses the varying effects of different vasoconstrictors, including naturally occurring substances and synthetic agents, on both normal and pathological cardiac conditions. Finally, it highlights the complex interactions between vasoconstrictors and other pharmacological interventions, suggesting areas for future research to improve therapeutic strategies for managing cardiovascular diseases linked to abnormal vascular tone regulation. ვაზოკონსტრიქტორები ფართოდ გამოიყენება სამედიცინო და სტომატოლოგიურ პრაქტიკაში, განსაკუთრებით ადგილობრივ საანესთეზიო საშუალებებში, წამლების ეფექტურობის გასახანგრძლივებლად და სისტემური აბსორბციის შესამცირებლად. მიუხედავად იმისა, რომ ვაზოკონსტრიქტორები ზოგადად უსაფრთხოდ ითვლება, გაჩნდა შეშფოთება გულ-სისხლძარღვთა სისტემაზე მათი ზემოქმედების შესახებ, განსაკუთრებით პაციენტებში, რომლებსაც აქვთ გულის დაავადება. სამეცნიერო ნაშრომი იკვლევს ვაზოკონსტრიქტორების როლს, მათ ფარმაკოლოგიურ მექანიზმებს და მათ პოტენციურ რისკებსა და სარგებელს კლინიკურ გარემოში. თანამედროვე ლიტერატურისა და კლინიკური გაიდლაინების მიმოხილვით, ჩამოყალიბდა დასკვნები და...

11 July 2025 in GEORGIAN SCIENTISTS
Verified
Journal Article
Open access
PDF file
Nodar SulashviliNodar Sulashvili
Nodar Sulashvili
RJRupali Digambar Jadhav
Rupali Digambar Jadhav
MBMargarita Beglaryan
Margarita Beglaryan
LGLuiza Gabunia
Luiza Gabunia
NGNana Gorgaslidze
Nana Gorgaslidze
KRKakhaber Robakidze
Kakhaber Robakidze
Drug-induced eosinophilia and systemic symptoms (DIES) represent a complex and potentially life-threatening spectrum of adverse drug reactions characterized by eosinophilic infiltration and multiorgan involvement. This review synthesizes current knowledge on the pharmacological, immunological, and clinical aspects of these reactions, with particular emphasis on severe manifestations such as drug reaction with eosinophilia and systemic symptoms (DRESS). We examine the mechanisms by which specific drug classes—including aromatic antiepileptics, antibiotics, and novel biologics—trigger eosinophil activation through hapten formation, direct T-cell stimulation, and cytokine release. Genetic predispositions, particularly HLA associations, and viral interactions (e.g., HHV-6 reactivation) are discussed as critical modulators of individual susceptibility and clinical severity. Recent advances in biomarker discovery (e.g., serum Siglec-8, eosinophil-derived extracellular traps) and imaging modalities (e.g., 68Ga-FAPI PET/CT) are evaluated for their diagnostic and prognostic utility. The review highlights emerging therapeutic strategies, including targeted biologics against IL-5/IL-33 and pharmacogenomic approaches to prevention, while underscoring persistent challenges in management, such as corticosteroid dependence and long-term sequelae. By integrating mechanistic insights with clinical observations, this work aims to refine diagnostic criteria, optimize therapeutic decision-making, and identify future research directions to mitigate the burden of these iatrogenic complications. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is an uncommon yet serious adverse drug reaction that presents with delayed systemic inflammation and multiple organ involvement. It is a member of the spectrum of severe cutaneous adverse reactions (SCAR), usually presenting 2–8 weeks post initiation of the culprit drug. Nonspecific symptoms, latency, and overlapping clinical findings with infections, autoimmune diseases, and other hypersensitivity reactions contribute to a failure to diagnose syndrome and worsening morbidity. The objective of this thesis is to conduct a comprehensive systematic review with emphasis on the pharmacological characteristics, clinical presentation, and genetic risk factors of DRESS syndrome, as well as a range of pathological drug classes, including anticonvulsants, antibiotics, allopurinol, and nonsteroidal anti-inflammatories (NSAIDs). The article also discusses treatment, long-term prognosis and research directions. The leading alternative agents were anticonvulsants (e.g., carbamazepine, phenytoin, lamotrigine), antibiotics (e.g., vancomycin, minocycline), allopurinol, and NSAIDs including mefenamic acid and ibuprofen. More than 60 % of cases had hepatic involvement; involvement of the kidneys (25 %) and the lungs (10–15 %) were also important. Nearly all patients presented with cutaneous findings, most commonly a diffuse morbilliform rash and facial edema, and frequently had fever and eosinophilia. Genetic predisposition is an important factor, with HLA-B58:01 allele in the context of allopurinol-induced DRESS, and HLA-A31:01 in the case of carbamazepine. These results emphasize the value of pharmacogenetic screening in high-risk population groups. Viral reactivation, including human herpesvirus-6 (HHV-6), had been observed in multiple patients and has contributed to overall disease severity and duration. Therapy consisted mainly in early discontinuation of the inducing agent and systemic corticosteroids. Although the majority of patients responded to corticosteroids, some became steroid resistant and were treated with medications such as cyclosporine, IVIG, and plasmapheresis. There is a lack of standardized treatment protocols, and randomized controlled trials are highly desired. Relapses during corticosteroid reduction or autoimmunity (type 1 diabetes, thyroiditis, lupus-like syndromes) occurred in some, but not in all patients. Multisystem DRESS syndrome mandates a high degree of clinical suspicion for early diagnosis and treatment. The underestimation of NSAID-induced DRESS emphasises the necessity for better pharmacovigilance tools and public awareness on OTC drug safety. Future advances would need to focus on the creation of general diagnostic criteria, useful biomarkers for early diagnosis, and the use of evidence-based algorithms for treatment.